 Pyridines
"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 1 | 0 | 1 | | 1995 | 0 | 1 | 1 | | 1998 | 1 | 1 | 2 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 4 | 5 | | 2002 | 1 | 4 | 5 | | 2003 | 1 | 4 | 5 | | 2004 | 2 | 4 | 6 | | 2005 | 2 | 1 | 3 | | 2006 | 3 | 3 | 6 | | 2007 | 6 | 2 | 8 | | 2008 | 6 | 4 | 10 | | 2009 | 6 | 1 | 7 | | 2010 | 5 | 5 | 10 | | 2011 | 4 | 4 | 8 | | 2012 | 9 | 9 | 18 | | 2013 | 9 | 6 | 15 | | 2014 | 8 | 6 | 14 | | 2015 | 9 | 3 | 12 | | 2016 | 11 | 8 | 19 | | 2017 | 7 | 4 | 11 | | 2018 | 2 | 1 | 3 | | 2019 | 6 | 5 | 11 | | 2020 | 1 | 0 | 1 | | 2021 | 9 | 11 | 20 | | 2022 | 2 | 4 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Matthews E, Schmitt B, Passeri M, Mizenko C, Orjuela K, Piquet A. AMPA Receptor Encephalitis in a Patient With Metastatic Breast Cancer Receiving Palbociclib: A Case Report. Neurol Neuroimmunol Neuroinflamm. 2022 Sep; 9(5).
-
Eisen DB, Dellavalle RP, Frazer-Green L, Schlesinger TE, Shive M, Wu PA. Focused update: Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2022 08; 87(2):373-374.e5.
-
Shaughnessy CA, Zeitlin PL, Bratcher PE. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro. J Cyst Fibros. 2022 Jul; 21(4):637-643.
-
Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am J Respir Crit Care Med. 2022 03 01; 205(5):529-539.
-
Narasimhan J, Letinski S, Jung SP, Gerasyuto A, Wang J, Arnold M, Chen G, Hedrick J, Dumble M, Ravichandran K, Levitz T, Cui C, Drennan CL, Stubbe J, Karp G, Branstrom A. Ribonucleotide reductase, a novel drug target for gonorrhea. Elife. 2022 02 09; 11.
-
Morrison JT, Govsyeyev N, Hess CN, Bonaca MP. Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease. J Cardiovasc Pharmacol Ther. 2022 Jan-Dec; 27:10742484211056115.
-
Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022 03; 33(3):321-329.
-
Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncol. 2021 Dec 01; 7(12):1815-1823.
-
O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021 Dec; 17(34):4665-4676.
-
Shaughnessy CA, Zeitlin PL, Bratcher PE. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Sci Rep. 2021 10 06; 11(1):19810.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|